



MGC Establishes a New Company for Contract Development of Antibody Drug Production Processes

 **MITSUBISHI GAS CHEMICAL COMPANY, INC.**

April 2, 2014

Mitsubishi Gas Chemical Company, Inc. (MGC; Head Office: Chiyoda-ku, Tokyo; President: Toshikiyo Kurai) has established a new company for contract R&D service operations including the process development of antibody drug : MGC Pharma Co., Ltd. (MGCP; Head office: Chiyoda-ku, Tokyo; President: Masami Orisaku).

A category of biotechnology-based pharmaceuticals taking advantage of antigen-antibody reaction (immunoreaction), antibody drugs are employed primarily in the treatment of cancer and immunological diseases as a replacement for conventional low-molecular medicine. The market for these therapeutic antibodies is now growing rapidly.

Through its research and development of biotechnology-based products such as coenzyme Q10, pyrroloquinoline quinone, and catalase, MGC has developed outstanding culture and purification technologies. In order to apply them to the production of antibody drugs, since 2010 the Company has introduced antibody drug production technology from GlycoNex Inc., a Taiwanese venture developing monoclonal antibody. It has worked with GlycoNex to develop contract R&D service operations.

With the establishment of a new company, MGC will develop relevant operations quicker than before and strengthen its competitiveness in the field which will allow MGC to win contracts manufacturing of substances used for antibody drugs. To this end, the Company will build organizations suitable for pharmaceutical operations, which includes those related to quality assurance and management systems.

Overview of MGCP

Company name: MGC Pharma Co., Ltd.

Address : Mitsubishi Building, Marunouchi 2-5-2, Chiyoda-ku, Tokyo
(the same building that houses MGC)

Establishment : April 2, 2014

Capital : 50 million yen

Shareholding : 100%-owned by MGC

Representative : Masami Orisaku, President

Business description: Contract research and sample production for antibody drugs

<Inquiries>

Corporate Communications Division

Tel: +81-(0)3-3283-5041